Overview

AB103 Peptide Antagonist in Healthy Volunteers

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Atox Bio Ltd